OPRX
OptimizeRx CorpPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Mar 5 OptimizeRx reported strong 2025 financial results with record revenu…
- R Mar 5 OptimizeRx (OPRX) reported solid Q4 and full-year 2025 results with…
- R Mar 5 OptimizeRx reported strong Q4 and full-year 2025 results with record…
- R May 12 OptimizeRx reported Q1 2026 revenue of $19.8M (down 10% YoY) and a G…
- R Aug 12 OptimizeRx reported Q2 2026 revenue of $20.5M and EPS of $0.14, beat…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q2 2026: 13 added (0 new), 24 trimmed or exited.
- AnalystsBULLISH
11 of 12 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate $0.246 → $0.162 over 90 days. 0 up, 1 down in 30 days.
- TrendUPTREND
12% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 19.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | TRIM | $2.5M |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $1.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | TRIM | $969.8K |
| MARSHALL WACE, LLP | DOUBLED | $927.7K |
| MORGAN STANLEY | DOUBLED | $894.1K |
| GOLDMAN SACHS GROUP INC | TRIM | $600.8K |
| Quantinno Capital Management LP | DOUBLED | $567.0K |
| Trexquant Investment LP | TRIM | $512.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is below the lowest target. Median implies +21%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 29, 2026 | B. Riley Securities MAINTAIN | Buy |
| Aug 14, 2026 | Citizens MAINTAIN | Market Outperform |
| May 13, 2026 | Lake Street MAINTAIN | Buy |
| May 13, 2026 | B. Riley Securities MAINTAIN | Buy |
| May 13, 2026 | Stephens & Co. MAINTAIN | Equal-Weight |
| May 13, 2026 | Stifel MAINTAIN | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 1, 2026 | D'Silva Andrew J. Chief Business Officer | TAX W/H | $3.5K |
| Sep 1, 2026 | D'Silva Andrew J. Chief Business Officer | TAX W/H | $11.3K |
| Aug 21, 2026 | Silvestro Stephen L Chief Executive Officer | TAX W/H | $13.4K |
| Aug 21, 2026 | Merrell Brendan W. CHIEF OPERATING OFFICER | TAX W/H | $7.9K |
| Aug 21, 2026 | Stelmakh Edward Chief Finance & Strat Officer | TAX W/H | $10.6K |
| Aug 21, 2026 | D'Silva Andrew J. Chief Business Officer | TAX W/H | $9.6K |
| Aug 21, 2026 | Odence-Ford Marion Chief Legal & Admin Officer | TAX W/H | $11.8K |
| Aug 20, 2026 | Silvestro Stephen L Chief Executive Officer | AWARD | 79,200 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.16 | $0.10–$0.22 | -4.7% | $21.2M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | $0.88 | $0.72–$0.99 | -1.6% | $96.2M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026SecBot reports
9 filings · 3 press releases · 2 bullish · 0 bearish · 3 mixed · 4 neutral- NEUTRAL SC 13G/AOct 21, 2026
Royce & Associates LP filed an amended Schedule 13G for OptimizeRx Corp, disclosing beneficial…
Monitor for any future conversion to Schedule 13D (activist intent) or significant changes in Royce's position. The 6.98% stake is just below the 10% threshold that would trigger additional…
- MIXED INST-CLUSTERSep 22, 2026
In Q2 2026, OptimizeRx saw a mixed institutional cluster: 13 buyers (led by Marshall Wace, Morgan…
The divergence between active quant buying and mega-passive selling suggests a potential catalyst-driven thesis among informed managers, but the net outflow and lack of insider corroboration warrant…
- BULLISH PRESS-RELEASEAug 12, 2026
OptimizeRx reported Q2 2026 revenue of $20.5M and EPS of $0.14, beating consensus estimates of…
The EPS beat and debt refinancing are positive, but the reaffirmation of existing guidance without an upgrade limits the upside catalyst.
- NEUTRAL 8-KJun 12, 2026
OptimizeRx held its 2026 Annual Meeting on June 9, 2026. Shareholders approved an amendment to the…
The rejection of the evergreen provision signals shareholder restraint on automatic dilution, but the approved share increase provides ample near-term equity for compensation. Monitor future proxy…
All OPRX filing & press-release reports (12)
- SC 13G/A reportOct 21, 2026
- INST-CLUSTER reportSep 22, 2026
- PRESS-RELEASE reportAug 12, 2026
- 8-K reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 5, 2026
- DEFA14A reportJun 1, 2026
- PRESS-RELEASE reportMay 21, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportMar 5, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026